The Royal Melbourne Hospital

Running trials

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Source

• Recruiting

  To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  NCT07629583· Phase 1· Source

• Not yet recruiting

  An Online Tailored Cognitive Therapy-Based Intervention for Depression in Multiple Sclerosis: ACTION-MS Online

  NCT07875309· Source

• Recruiting

  A Study in Adults With Geographic Atrophy

  NCT07606365· Phase 2· Source

• Active, not recruiting

  Functional Outcomes and Control Using Synchron BCI - Australia

  NCT07533903· Source

• Recruiting

  A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

  NCT07536061· Phase 1· Source

• Enrolling by invitation

  An Extension of SKY-0515 in Participants With Huntington's Disease

  NCT07537075· Phase 2/3· Source

• Recruiting

  Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

  NCT07298473· Source

• Not yet recruiting

  Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

  NCT07527819· Source

• Recruiting

  A Gaucher Disease Gene Therapy Trial With FLT201

  NCT07223944· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  NCT07291076· Phase 1/2· Source

• Recruiting

  Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

  NCT07122258· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Source

• Not yet recruiting

  Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin

  NCT07225465· Phase 2· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Source

• Recruiting

  SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

  NCT07187531· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

  NCT07246941· Phase 1· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Source

• Recruiting

  A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

  NCT07118241· Phase 2· Source

• Recruiting

  Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

  NCT07055542· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

  NCT07082725· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

  NCT07054515· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

  NCT06782490· Phase 2· Source

• Active, not recruiting

  Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

  NCT06735534· Source

• Recruiting

  Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

  NCT06850727· Phase 2· Source

• Active, not recruiting

  Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

  NCT06873334· Phase 2/3· Source

• Active, not recruiting

  Pomalidomide as an Immune-enhancing Agent for the Control of HIV

  NCT06660498· Phase 1/2· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Source

• Recruiting

  Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

  NCT06999122· Source

• Recruiting

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

  NCT06732180· Phase 1· Source

• Recruiting

  Implementing Surgery School Prehabilitation Using Telehealth

  NCT06631872· Source

• Recruiting

  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  NCT06613360· Phase 1· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Source

• Recruiting

  A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  NCT06667908· Phase 2· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Source

• Recruiting

  VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

  NCT06257706· Phase 4· Source

• Not yet recruiting

  Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke

  NCT06495671· Source

• Recruiting

  Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

  NCT06226805· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke8 recruiting
• Epilepsy5 recruiting
• Type 1 diabetes5 recruiting
• Huntington's disease4 recruiting
• Lung cancer4 recruiting
• Parkinson disease4 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Alzheimer disease2 recruiting
• Crohn's disease2 recruiting
• Heart failure2 recruiting
• Lupus (SLE)2 recruiting
• Multiple sclerosis2 recruiting
• Prostate cancer2 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Depression1 recruiting
• Gaucher disease1 recruiting
• Hepatitis B1 recruiting
• Liver and biliary tract cancer1 recruiting
• Macular degeneration1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Sjögren's disease1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

  NCT06961344· Phase 2· Source

• Completed

  A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke

  NCT06987643· Phase 2· Source

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· Source

• Withdrawn

  Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

  NCT06598631· Phase 2· Source

• Completed

  A Phase 2b Study of Zagociguat in Patients With MELAS

  NCT06402123· Phase 2· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Source

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Source

• Completed

  Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device

  NCT07751328· Source

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06326047· Phase 2· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Source

• Completed

  BPL-003 Efficacy and Safety in Treatment Resistant Depression

  NCT05870540· Phase 2· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Source

• Completed

  First in Human Study to Assess an Implant to Treat Severe Emphysema

  NCT05854550· Source

• Completed

  Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes

  NCT05742243· Phase 2· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Source

• Terminated

  Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT05425862· Phase 1· Source

• Completed

  A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

  NCT05174221· Phase 1· Source

• Completed

  A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  NCT05452239· Phase 4· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Source

• Completed

  Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

  NCT05203224· Phase 2· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Source

• Completed

  Hepatocellular Carcinoma Imaging Using PSMA PET/CT

  NCT05095519· Phase 2· Source

• Completed

  Study of WVE-003 in Patients With Huntington's Disease

  NCT05032196· Phase 1/2· Source

• Completed

  Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

  NCT04891770· Phase 2· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Source

• Completed

  Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

  NCT04750226· Phase 3· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· Source

• Completed

  Baricitinib in New-onset Type 1 Diabetes

  NCT04774224· Phase 2· Source

• Terminated

  Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion

  NCT04454788· Phase 3· Source

• Terminated

  Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

  NCT04316013· Phase 3· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· Source

• Terminated

  Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

  NCT04171141· Phase 1· Source

• Completed

  SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

  NCT03876457· Source

• Completed

  Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

  NCT03900884· Phase 1· Source

• Completed

  Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

  NCT04046224· Phase 1/2· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Source

• Completed

  A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

  NCT03737214· Phase 3· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Source

Trial sites

• Dept of Neurology, The Royal Melbourne Hospital1 trial
• Melbourne Health - The Royal Melbourne Hospital1 trial
• Royal Melbourne Hospital38 trials
• Royal Melbourne Hospital, also known as RMH Parkville1 trial
• The Royal Melbourne Hospital7 trials
• Melbourne Health - Royal Melbourne Hospital1 trial
• Royal Melbourne Hospital76 trials
• Royal Melbourne Hospital - City Campus3 trials
• Royal Melbourne Hospital - Department of Nephrology1 trial
• Royal Melbourne Hospital Parkville1 trial
• Royal Melbourne Hospital (RMH)1 trial
• Royal Melbourne Hospital, University of Melbourne1 trial
• The Royal Melbourne Hospital42 trials
• The Royal Melbourne Hospital - Diabetes & Endocrinology Department3 trials
• The Royal Melbourne Hospital /ID# 1248461 trial
• The Royal Melbourne Hospital /ID# 1550951 trial
• The Royal Melbourne Hospital /ID# 1579931 trial
• The Royal Melbourne Hospital /ID# 2059191 trial
• The Royal Melbourne Hospital /ID# 2184191 trial
• The Royal Melbourne Hospital /ID# 2401781 trial
• The Royal Melbourne Hospital /ID# 2483531 trial
• The Royal Melbourne Hospital /ID# 2596711 trial
• The Royal Melbourne Hospital /ID# 97811 trial
• The Royal Melbourne Hospital (RMH)1 trial
• The Royal Melbourne Hospital (Site 1602)1 trial
• University of Melbourne, Royal Melbourne Hospital1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke138 works · 21 trials
• Atrial fibrillation62 works · 7 trials
• Prostate cancer50 works · 4 trials
• Multiple sclerosis47 works · 4 trials
• Epilepsy44 works · 10 trials
• Multiple myeloma31 works · 2 trials
• Type 1 diabetes23 works · 10 trials
• Chronic lymphocytic leukaemia16 works · 2 trials
• Follicular lymphoma9 works · 0 trials
• Myelodysplastic syndromes8 works · 1 trials
• Mantle cell lymphoma8 works · 0 trials
• Hepatitis B7 works · 2 trials
• Myeloproliferative neoplasms6 works · 1 trials
• Fabry disease5 works · 6 trials